Share
News
-
25 February 2009 /Side effects and trials
The benefits of ADHD medicine exceed the risks
The benefits of the medicine exceed the risks when children and young people with activity and attention problems - ADHD (attention deficit hyperactivity disorder) - are given medicine containing the substance methylphenidate.
-
23 February 2009 /Side effects and trials
The European Medicines Agency (EMEA) continues to recommend vaccination with Gardasil®
EMEA has reviewed two cases from Spain, where two girls experienced prolonged and severe seizures with loss of consciusness after they had been vaccinated with the cervical cancer vaccine Gardasil®.
-
20 February 2009 /Side effects and trials
The European Medicines Agency (EMEA) recommends the European Commission to suspend the marketing authorisation of Raptiva®
The Committee for Medicinal Products for Human Use (CHMP) under EMEA has concluded that the benefit of the medicinal product Raptiva® (efalizumab) for patients with moderate plaque psoriasis can no longer justify the risk of a number of serious adverse reactions, first and foremost progressive multifocal leukoencephalopathy (PML)
-
16 February 2009 /Side effects and trials
Atopic dermatitis and vaccination with Gardasil®
The HPV vaccine Gardasil® provides protection for cervical cancer. The vaccine has been on the Danish market since 2006. As of 1 January 2009, the vaccine is included in the Danish childhood immunisation programme as an offer for all 12-year-old girls.
-
03 February 2009 /Side effects and trials
The MRI contrast agent Dotarem®
Dotarem® is a gadolinium-containing contrast agent used in connection with MRI scanning. Gadolinium-containing contrast agents must be used with extreme care when scanning patients with renal impairment because these patients excrete the contrast agent significantly slower than patients with normal renal function.
-
16 January 2009 /Side effects and trials
The use of Omniscan for kidney patients
In February 2007, the Danish Medicines Agency changed its recommendations concerning the use of Omniscan for kidney patients due to a strong suspicion that the contrast medium may cause the serious adverse reaction: Nephrogenic Systemic Fibrosis
